Toll Free 24/7 Customer Service
1-855-226-9242
SURMOUNT-1 is an obesity drug trial for Tirzepatide that is currently going through the clinical trials to determine whether it is safe and effective. This medication has not yet received the approval it needs from the US Food and Drug Administration (FDA) to be legally prescribed and sold in the United States. That said, it is in the process of doing so.
The obesity disease is a rising problem in the United States and many other countries around the world. It is straining people’s health and countries’ health systems. As a result, many pharmaceutical companies are working hard to develop more obesity drugs to help those patients to lose weight safely and effectively, and while simultaneously reducing their risk of other health conditions such as heart disease, type 2 diabetes, and certain types of cancers, among others.
SURMOUNT-1 is testing one of the medications developed for this purpose. Eli Lilly is testing the drug, with the generic name of tirzepatide. The goal is to successfully complete its testing so that doctors will one day be able to prescribe it to obesity patients. At the moment, doctors cannot legally prescribe it. You can not purchase this drug and should not trust any individual or company offering it to you in the United States.
The research so far for SURMOUNT-1 has been quite promising. The clinical trial showed that an average of 16 percent of body weight was lost after 72 weeks of use (16 and a half months).
The drug has been undergoing a phase 3 trial involving 2,539 adult participants. What they have found so far was that when compared to the participants who were given a placebo, those taking the tirzepatide-based drug lost 5 percent of their overall body weight.
Adults who were randomly assigned the SURMOUNT-1 drug Tirzepatide achieved an average body weight loss of 16 percent when taking a 5mg dose. Those assigned a 10 mg dose lost an average of 21.4 percent of their body weight in the same amount of time. Those using 15 mg lost 22.5 percent of their body weight in the same amount of time. The placebo group lost an average of 2.4 percent during that same timespan.
Among those who were taking the SURMOUNT-1 drug Tirzepatide, 89 percent lost at least 5 percent of their body weight. In the placebo group, only 28 percent lost at least 5 percent of their body weight.
Additional studies are ongoing, but this does suggest that this is a highly promising obesity drug. If it proves adequately safe, it could become a medication prescribed by doctors in the United States.
